Results 201 to 210 of about 159,806 (339)
Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment [PDF]
, 2016 Anton Tomšič +4 more
openalex +1 more source
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
New England Journal of Medicine, 2017 L. Søndergaard +11 more
semanticscholar +1 more source
Novel Simplified Nasal Endoscopy Grading System for Hereditary Hemorrhagic Telangiectasia Patients
The Laryngoscope, EarlyView.We validated a novel, simplified nasal endoscopy grading system for patients with Hereditary Hemorrhagic Telangiectasia (HHT). Our grading (mild, moderate, severe) demonstrated strong correlation with Epistaxis Severity Score (ESS) and Quality of Life (QoL), and showed substantial inter‐rater reliability (ICC = 0.8).
Ethan Soudry +4 more
wiley +1 more source
Exogenous factors as potential antiplatelet drugs [PDF]
, 2021 Danique van den Kerkhof
openalex +1 more source
Lipids, EarlyView.ABSTRACT Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid‐lowering
Chao Zhao +5 more
wiley +1 more source
Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement [PDF]
, 2012 Wael El Mallah, David J. Moliterno
openalex +1 more source
Obesity, EarlyView.ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu +13 more
wiley +1 more source
Prior antiplatelet or anticoagulant therapy and mortality in stroke [PDF]
, 2012 Chun Shing Kwok +4 more
openalex +1 more source
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
New England Journal of Medicine, 2014 L. Mauri +23 more
semanticscholar +1 more source
Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events
CPT: Pharmacometrics &Systems Pharmacology, EarlyView.ABSTRACT Asundexian is a potent, selective, and reversible inhibitor of activated clotting Factor XI currently under development for secondary prevention of recurrent ischemic stroke in the ongoing Phase III OCEANIC‐STROKE study (NCT05686070). Here, we report the development of a population pharmacokinetic (popPK) model for asundexian.
Ashraf Yassen +7 more
wiley +1 more source